Sofinnova Partners has announced the close of its latest flagship fund, Sofinnova Capital XI, securing €650 million ($750 million) and surpassing its original fundraising target. The firm, which operates from Paris, London and Milan, said the new fund contributes to a total of €1.5Bn raised across its platform over the past year.
Sofinnova Capital XI will focus on early-stage biopharmaceutical and medtech companies developing solutions for urgent unmet clinical needs. The fund builds on Sofinnova’s long-standing multi-strategy model and draws on the expertise of its team of Partners: Maina Bhaman, Anta Gkelou, Karl Naegler, Antoine Papiernik, Henrijette Richter and Graziano Seghezzi.
The fundraising attracted a wide global base of institutional investors, including sovereign wealth funds, leading pharmaceutical companies and other corporates, as well as insurance companies, foundations and family offices. Commitments came from across Europe, North America, Asia and the Middle East. Sofinnova reported strong participation from returning limited partners alongside a notable number of new investors, indicating a sustained level of confidence in the firm’s investment approach.
Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, said: “This fundraising marks a pivotal moment for Sofinnova. It gives us the firepower to double down on early-stage opportunities and reinforces our uniquely collaborative, science-driven investment approach. We’re excited to continue backing visionary entrepreneurs and advancing the next wave of breakthroughs in science and medicine to bring them to patients worldwide.”
He added: “Achieving this milestone in today’s volatile fundraising environment speaks to the strength of our model and the confidence our investors continue to place in us.”
Sofinnova confirmed that Capital XI is already deploying funding, with several investments made in its early portfolio. The firm plans to continue supporting biotech and medtech companies across Europe and North America through initial and follow-on rounds. According to Sofinnova, the fund’s strategy remains centred on identifying high-potential scientific innovation and working closely with founders to support growth, development and commercial progress.
The close of Capital XI reinforces Sofinnova’s position as one of Europe’s leading life sciences venture firms, adding significant capacity to build and scale companies targeting transformative advancements in healthcare.
